BRAF and Marfan syndrome: Although cell of origin of MFS remains to be unknown, this suggests that promoter swapping between BRAF and SLC37A3 by structural rearrangement may increase expression of SLC37A-BRAF fusion gene compared to that of wild-type BRAF. Although BRAF fusion has been recently identified in a subset of myxoinflammatory fibroblastic sarcoma56, our MFS with BRAF fusion showed no findings that may suggest relationship with this rare low-grade acral sarcoma.